Developing a unique hybridoma platform for manufacturing mAb cocktail formulations
Learn how Syngene developed a unique hybridoma platform for manufacturing mAb cocktail formulations for use in reagent kits designed to activate and expand human T cells for immunotherapy in patients.
Harnessing the immune system for cancer cell-therapy
Explore the top challenges in developing CAR-T therapy for treating cancer and how leading CRO-CDMO Syngene supports clients in bringing this therapy to patients faster.
Development of a Scalable Process for the Synthesis of Cyclopropyl-Methyl-Proline with Complex Stereochemistry: A Key Building Block of Factor D Inhibitors
Publication: ACS Publications
Quantifying a biomarker in mice brain for treating mood and anxiety disorders
A robust LC-MS-based quantitative method developed at Syngene to measure biomarker 2-AG in mice brain tissues for treating mood and anxiety disorders.
SynWeaveTM: Integrating Speed, Titer and Quality webinar
BWC0977, a broad-spectrum antibacterial clinical candidate to treat multidrug resistant infections
Publication: Nature Communications
Enhancing nanofiltration efficiency in mAb production process
Learn how Syngene enabled a major pharma company optimize the nanofiltration process to achieve efficient viral clearance while lowering operational costs.
Characterizing and predicting physical properties of hydrocarbon mixtures using AI
Learn how Syngene developed an artificial intelligence (AI) tool to reliably predict the physical properties of long-chain hydrocarbon mixtures.
Risk assessment strategy for nitrosamine drug substance-related impurities
The potential causes of nitrosamine drug substance-related impurities and Syngene’s strategic framework for identification and management of these impurities to meet regulatory guidelines for product safety.
Systematic mutational analysis reveals an essential role of N275 in IgE stability
Publication: Biotechnology and Bioengineering, Wiley